Globe Newswire
NASSAU, the Bahamas, June 03, 2024 (GLOBE NEWSWIRE) -- OKX, a leading crypto exchange and Web3 technology company, has issued updates for June 3, 2024.
OKX Announces Enhancements to Portfolio Margin Mode to Optimize Trading Experience
OKX has announced new enhancements to its portfolio margin mode to further optimize the trading experience for its customers. These updates are set to go live at 4:00 AM (UTC) on June 5, 2024.
The update includes richer offset... (continue reading...)
BW Energy: Fixed Income Investor Meetings
BW Energy has engaged DNB Markets, a part of DNB Bank ASA and Pareto Securities AS as Joint Bookrunners to arrange a series of fixed income investor meetings. Subject to inter alia market conditions and acceptable terms, a new senior unsecured bond issue of USD 100 million with a tenor of five years may follow. The purpose of the bond issue is for general corporate purposes.
For further information, please contact:
... (continue reading...)Press release
Andre Lacerda Appointed Senior Vice President of South America (Tubes Activities)
Meudon (France), June 3rd 2024 – Vallourec, a world leader in premium tubular solutions, announces the appointment of Andre Lacerda as Senior Vice President South America for the Tubes segment. In this capacity, he joins the Group's Executive Committee and will report to Bertrand Frischmann, Chief Operating Officer of the Americas.
Andre Lacerda has extensive... (continue reading...)
BOUSSARD & GAVAUDAN HOLDING LIMITED
Ordinary Shares
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
Close of business 31 May 2024.
Estimated NAV
Euro Shares Sterling Shares Estimated NAV € 28.0156 £ 25.1139 Estimated MTD return 1.19 % 1.29 % Estimated YTD... (continue reading...)BOUSSARD & GAVAUDAN HOLDING LIMITED
Ordinary Shares
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
Close of business 31 May 2024.
Estimated NAV
Euro Shares Sterling Shares Estimated NAV € 28.0156 £ 25.1139 Estimated MTD return 1.19 % 1.29 % Estimated YTD... (continue reading...)More Globe Newswire
View Older Stories-
Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
-
Number of voting rights as of May 31, 2024
-
BW Energy: Appraisal confirms material Hibiscus field reserve increase
-
Market Update
-
Start of Day Message
-
Ontex finalizes the divestment of its business in Pakistan
-
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
-
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
-
Corbion reports the progress of its € 20 million share buyback program 27 May – 31 May 2024
-
New data with daridorexant to be presented at SLEEP 2024
-
Flash News: OKX to Support Mina Protocol's Upgrade
-
Flash News: OKX to Support Mina Protocol's Upgrade
-
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
-
NetAlly Unveils Next Generation LinkRunner® AT Network and Cable Testers
-
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
-
IXOPAY Appoints Brady Harris as CEO to Drive Global Payments Growth
-
AMD Unveils Next-Gen “Zen 5” Ryzen Processors to Power Advanced AI Experiences
-
AMD Accelerates Pace of Data Center AI Innovation and Leadership with Expanded AMD Instinct GPU Roadmap
-
AMD Extends AI and High-Performance Leadership in Data Center and PCs with New AMD Instinct, Ryzen and EPYC Processors at Computex 2024
-
Flash News: OKX Launches 100% Fee Rebate Campaign
-
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
-
Mesoblast Corporate Presentation at Investor Conference
-
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
-
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
-
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
-
Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year
-
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
-
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
-
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
-
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
-
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
-
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
-
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 The
-
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
-
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple
-
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
-
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
-
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines
-
Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse
-
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs
-
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution
-
NVIDIA Supercharges Ethernet Networking for Generative AI
-
GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
-
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers
-
NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars
-
CryptoHeap Launches Comprehensive Strategy for Crypto Staking Amidst Market Fluctuations
-
William Miller Spearheads Launch of Pioneering OkayCoin Staking Protocol
-
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
